Compliance of sildenafil treatment for erectile dysfunction and factors affecting it

被引:61
作者
Jiann, BP
Yu, CC
Su, CC
Tsai, JY
机构
[1] Kaohsiung Vet Gen Hosp, Dept Surg, Div Urol, Kaohsiung 813, Taiwan
[2] Yuans Gen Hosp, Dept Urol, Kaohsiung, Taiwan
关键词
compliance; discontinuation; sildenafil; erectile dysfunction; phosphodiesterase type 5 inhibitors;
D O I
10.1038/sj.ijir.3901379
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
To assess the compliance of treatment, its affecting factors, and reasons for dropout, a questionnaire was mailed to a cohort of 2139 subjects who received sildenafil prescriptions for erectile dysfunction (ED) at our institution from 1999 to 2002. A total of 726 subjects (34%) with a mean age of 67 years answered the questionnaires. The response rate for sildenafil treatment was 67%. Of these sildenafil responders, 43% reported that they continued using sildenafil while 57% did not, in a mean follow-up of 3 years. Common reasons for discontinuation were effect below expectations, high cost, loss of interest in sex, and inconvenience in obtaining sildenafil. The continuers showed a higher rate than the discontinuers (P < 0.05) of having tried other treatments, dose titration, and a dose higher than 50 mg. The discontinuers reported having a lower mean responding dose and improvement score post sildenafil treatment than the continuers. In conclusion, effect below expectations was the leading reason for discontinuation of sildenafil treatment. How ED subjects tried the medication and the adequacy of education in the initial treatment period may impact the compliance of sildenafil treatment.
引用
收藏
页码:146 / 149
页数:4
相关论文
共 10 条
[1]  
HACKETT GI, 2001, 4 C EUR SOC SEX IMP
[2]   Health outcomes variables important to patients in the treatment of erectile dysfunction [J].
Hanson-Divers, C ;
Jackson, SE ;
Lue, TF ;
Crawford, SY ;
Rosen, RC .
JOURNAL OF UROLOGY, 1998, 159 (05) :1541-1547
[3]   The diffusion of a novel therapy into clinical practice -: The case of sildenafil [J].
Harrold, LR ;
Gurwitz, JH ;
Field, TS ;
Andrade, SE ;
Fish, LS ;
Jarry, PD ;
Yood, RA .
ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (22) :3401-3405
[4]   Impact of introduction of sildenafil on other treatment modalities for erectile dysfunction: a study of nationwide and local hospital sales [J].
Jiann, BP ;
Yu, CC ;
Su, CC .
INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, 2004, 16 (06) :527-530
[5]   What to learn about sildenafil in the treatment of erectile dysfunction from 3-year clinical experience [J].
Jiann, BP ;
Yu, CC ;
Tsai, JY ;
Wu, TT ;
Lee, YH ;
Huang, JK .
INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, 2003, 15 (06) :412-417
[6]   Why do patients with erectile dysfunction abandon effective therapy with sildenafil (Viagra®)? [J].
Klotz, T ;
Mathers, M ;
Klotz, R ;
Sommer, F .
INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, 2005, 17 (01) :2-4
[7]   Erectile dysfunction in the elderly: Epidemiology, etiology and approaches to treatment [J].
Seftel, AD .
JOURNAL OF UROLOGY, 2003, 169 (06) :1999-2007
[8]  
Son H, 2004, ASIAN J ANDROL, V6, P117
[9]  
vw Casabe A, 2001, INT J IMPOT RES S2, V13, pS5
[10]   Use of medications for erectile dysfunction in the United States, 1996 through 2001 [J].
Wysowski, DK ;
Swann, J .
JOURNAL OF UROLOGY, 2003, 169 (03) :1040-1042